Affidea launches neuraCare — Europe’s first pan-European network of Centres of Excellence in Neurology
Flagship centre opens in Athens, Greece, with a transformative model for patient-centered neurological care across Europe
The Hague, The Netherlands, September 30th, 2025: Affidea, a leading European provider of community-based polyclinics, advanced diagnostics and specialised services, has officially launched Affidea neuraCare, a pioneering network of Centres of Excellence in Neurology, where clinical expertise, research and holistic support come together to deliver better outcomes for people living with neurological conditions.
With a double-digit million-euro investment, Affidea opened its first flagship neuraCare centre in Athens, Greece, marking the start of a European rollout that will reach seven centres in the next period, with planned locations such as Warsaw and London. The network responds to the urgent need for more integrated, innovative and patient-focused neurology care as disorders such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis (MS), epilepsy and severe migraines rise sharply across Europe.
Guy Blomfield, Chairman of the Management Board & Group CEO of Affidea, said:
“The launch of Affidea neuraCare represents an entirely new step change for how neurology care is delivered in Europe. We have built a multidisciplinary model that brings world-class physicians, advanced technology and clinical research together to improve outcomes and patient experience. Equally important, we believe that progress in healthcare comes from strong public–private partnerships, working alongside governments, universities and patient organisations to make advanced neurological care accessible and sustainable. By shifting care closer to communities, accelerating diagnoses and empowering patients and families, we aim to be at the forefront in enhancing the way neurological conditions are managed.”
Affidea neuraCare introduces a new approach to neurology by leveraging state-of-the-art technologies, novel tracers, digital innovations and outstanding clinical expertise. This combination enables earlier and more precise diagnosis, more effective treatment and improved long-term follow-up, while also expanding patient access across Europe.
Dr. Charles Niehaus, Executive Director for Affidea Group, added: “Today, neurological conditions affect one in six Europeans and demand is growing faster than most health systems can respond. NeuraCare was designed to change this trajectory. We are building fully integrated pathways, from prevention and early detection to advanced treatments, clinical trials, and long-term monitoring, all delivered within a single, seamless patient journey. NeuraCare is not just a new service line, it is a new model of care.”
Professor Marios Politis, Chairman of Affidea neuraCare Europe, noted: “This is not just another medical facility, it is true care as it should be. We inaugurated a vision for the future of neurological care. Affidea neuraCare is being built on unified standards, strong collaborations in research and technology, and a patient-first philosophy. Our centres will bring earlier and more accurate diagnosis, innovative therapies and faster access to life-changing research.”
About Affidea neuraCare Athens — The first flagship Centre of Excellence
Affidea neuraCare Athens is the model for the network’s expansion. Purpose-built over 1,500 m² across two floors, it offers a seamless continuum of neurological care, from prevention and early screening to fast, accurate diagnosis, targeted therapy, long-term monitoring and research participation, in an outstanding facility that was designed with patient comfort in mind.
Key services include:
- Advanced diagnostics — neurological consultations, digital neurocognitive assessments, full pathology labs, and a diagnostic imaging suite equipped with the most advanced systems, including PET/CT Omni Legend, the SIGNA™ Hero 3T MRI scanner and SPECT/CT, technology underpinned by GE HealthCare’s globally recognised standards of quality and performance.
- Comprehensive therapies — neuropsychology, neurological botox, digital and wearable-enabled monitoring, telehealth follow-up and continuous cognitive assessment.
- Clinical research hub — direct patient access to academic, pharmaceutical and industry-led trials, including dementia-focused tracer validation.
For the first time in Greece and Europe, world-renowned neurologists have come together under one roof to redefine standards of care for patients with neurological conditions.
Theodoros Karoutzos, CEO of Affidea Greece, commented during the launch event: “Today is a landmark day for health in Greece. As we celebrate two decades of innovation and quality, we inaugurate the first Centre of Excellence in Neurology in our country and Europe. Our mission remains to bring science closer to people and to build the future of healthcare today.”
An early milestone will be the implementation of a clinical protocol study at the Athens centre, conducted under the leadership of Professor Marios Politis. The study will evaluate the use of novel tracers to strengthen the accuracy of dementia diagnosis, providing a structured pathway for advancing clinical knowledge and practice. In this context, Affidea has entered into a first-of-its-kind partnership with GE HealthCare, combining the sensitivity and speed of the PET/CT Omni Legend, advanced digital innovations (including those from MIM Software), and Affidea’s recognised clinical know-how. This collaboration will enable the development of a dedicated, data-driven neurology module using novel tracers, a major step forward in linking imaging excellence with clinical decision-making.
A Scientific Committee of leading European neurologists has been established to guide the initiative, ensure clinical excellence and elevate recognition at European level.
Prof. Dr. Jin Yamamura, General Manager, Digital Solutions & Care Pathways, Enterprise Solutions, GE HealthCare, said: This initiative exemplifies how GE HealthCare’s advanced technologies and digital health solutions extend far beyond imaging equipment. By integrating precision diagnostics, collaborative research, and scalable innovation, we enable more personalised, accessible, and impactful care for patients. We are proud to collaborate with Affidea in shaping a new era in neurology - where clinical excellence meets meaningful outcomes”.
To learn more about Affidea neuraCare, access: www.affidea-neuracare.gr
Affidea neuraCare video: https://youtu.be/uOqk3l8GUjc
About Affidea Group
Affidea (www.affidea.com) is a leading pan-European provider of specialist healthcare services, community-based polyclinics and advanced diagnostic imaging. Founded in 1991, the company operates over 415 centres across 15 countries, with more than 14 million patient visits every year. Due to its track record for patient safety, the company has become the most awarded diagnostic imaging provider in Europe by the European Society of Radiology (ESR), as over 90% of its centres are recognised on the Eurosafe Wall of Stars by the ESR. Affidea is majority-owned by Groupe Bruxelles Lambert (GBL), a leading investment holding company, focused on long-term value-creation with a stable and supportive family shareholder base.
About Affidea Greece
Affidea medical centres have been operating in Greece since 2005 through a nationwide network, and they are contracted with EOPYY, all public health funds, and private insurance companies. Affidea’s medical technology equipment is the most youngest in Europe, featuring advanced systems for MRI and CT scans, 3D digital mammography, and ultrasound imaging, with technology designed to prioritize patient care. All centres are certified according to the international ISO 9001 standard, while the biopathology laboratories are accredited by the Hellenic Accreditation System (E.SY.D.) under ISO 15189. Affidea diagnostic centres have been awarded and included in the “EuroSafe Wall of Stars” list as among the safest in Europe in terms of radiation protection, as they exclusively apply the Dose Excellence radiation dose management program during CT examinations.